Accounts Payable and Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2026

8. Accounts Payable and Accrued Expenses and Other Current Liabilities

Accounts payable as of March 31, 2026, included $9.4 million of offering expenses related to the 2026 Private Placement discussed in Note 9.

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31, 2026		December 31, 2025
Accrued compensation and ESPP contributions	$	1,115	$	2,693
Accrued outsourced non-clinical studies		938		651
Accrued contract manufacturing costs		360		223
Accrued clinical trial costs		95		49
Accrued other		390		323
Total accrued expenses and other current liabilities	$	2,898	$	3,939